MYIA
ALNY icon

Mount Yale Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mount Yale Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$396K Buy
1,316
+53
+4% +$16K 0.01% 871
2026
Q1 		$418K Buy
+1,263
New +$430K 0.01% 775
2025
Q3 		– Sell
-113
Closed -$36.8K – 708
2025
Q2 		$36.8K Buy
+113
New +$31.3K ﹤0.01% 897

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mount Yale Investment Advisors's ALNY Position: Q2 2026 in Review

Mount Yale Investment Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 4.2% in Q2 2026, buying an estimated $16K and bringing the position to 1,316 shares worth $396K. The position accounts for 0.01% of the portfolio, ranked #871.

Mount Yale Investment Advisors first reported a position in ALNY in Q2 2025 and has held it in 3 quarters since. The position peaked at $418K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Mount Yale Investment Advisors held 1,316 shares of Alnylam Pharmaceuticals worth $396K as of Q2 2026.
  • Mount Yale Investment Advisors bought 53 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $16K.
  • Alnylam Pharmaceuticals made up 0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #871 holding.
  • Mount Yale Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Mount Yale Investment Advisors's Alnylam Pharmaceuticals position peaked at $418K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.